Anixa Biosciences Inc (NASDAQ:ANIX) Stock Now Rated “Hold” by Wall Street Analysts

Anixa Biosciences Inc (NASDAQ:ANIX) has earned a consensus rating of “Hold” from the five ratings firms that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have issued a buy recommendation on the company. The average 12 month price target among analysts that have covered the stock in the last year is $8.00.

A number of brokerages have commented on ANIX. Weiss Ratings upgraded shares of Anixa Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, September 17th. D. Boral Capital reaffirmed a “buy” rating and set a $10.00 target price on shares of Anixa Biosciences in a research report on Tuesday, June 30th. Citigroup reaffirmed a “buy” rating on shares of Anixa Biosciences in a research report on Tuesday, October 6th. HC Wainwright decreased their price target on shares of Anixa Biosciences from $7.00 to $6.00 and set a “buy” rating for the company in a research note on Tuesday, September 22nd. Finally, Zacks Research lowered Anixa Biosciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 19th.

Insider Transactions at Anixa Biosciences

In other news, Director Lewis Titterton, Jr. acquired 49,036 shares of Anixa Biosciences stock in a transaction on Wednesday, September 23rd. The shares were bought at an average cost of $2.69 per share, for a total transaction of $131,906.84. Following the acquisition, the director directly owned 1,046,003 shares of the company’s stock, valued at $2,813,748.07. This trade represents a 4.92% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders purchased a total of 100,724 shares of company stock valued at $286,620 over the last quarter. 26.40% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Anixa Biosciences

A number of institutional investors and hedge funds have recently bought and sold shares of ANIX. Renaissance Technologies LLC grew its holdings in shares of Anixa Biosciences by 13.6% during the first quarter. Renaissance Technologies LLC now owns 61,173 shares of the company’s stock valued at $158,000 after buying an additional 7,300 shares during the last quarter. CoreCap Advisors LLC increased its position in shares of Anixa Biosciences by 19.2% in the 3rd quarter. CoreCap Advisors LLC now owns 62,020 shares of the company’s stock valued at $182,000 after acquiring an additional 10,000 shares during the period. Sanctuary Advisors LLC purchased a new position in Anixa Biosciences in the 2nd quarter worth $29,000. Northwestern Mutual Wealth Management Co. purchased a new position in Anixa Biosciences in the 2nd quarter worth $29,000. Finally, Integrated Wealth Concepts LLC purchased a new position in Anixa Biosciences in the 2nd quarter worth $30,000. 29.13% of the stock is owned by institutional investors.

Anixa Biosciences Trading Down 2.2%

Shares of ANIX opened at $2.61 on Thursday. The firm has a market capitalization of $90.72 million, a P/E ratio of -8.16 and a beta of 0.47. Anixa Biosciences has a 12-month low of $2.32 and a 12-month high of $5.46. The firm has a fifty day moving average price of $3.03 and a 200-day moving average price of $2.98.

Anixa Biosciences (NASDAQ:ANIX) last posted its quarterly earnings results on Wednesday, September 9th. The company reported ($0.08) EPS for the quarter, hitting analysts’ consensus estimates of ($0.08). Analysts predict that Anixa Biosciences will post -0.31 earnings per share for the current year.

About Anixa Biosciences

Anixa Biosciences, Inc is a clinical-stage biotechnology company focused on developing immunotherapies and vaccines for cancer and infectious diseases. Rather than marketing a broad portfolio of commercial products, the company concentrates on advancing novel therapies through research collaborations and clinical development.

Anixa’s cancer programs include a breast cancer vaccine intended to target alpha-lactalbumin, a protein associated with certain breast cancers. The program is being developed in collaboration with researchers at Cleveland Clinic.